 Connection
Joseph Saseen to Cohort Studies
This is a "connection" page, showing publications Joseph Saseen has written about Cohort Studies.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.286 |
|
|
|
-
Tunoa JA, Billups SJ, Lowe RN, Saseen JJ. Early impact of the 2018 AHA/ACC/multisociety cholesterol guideline on lipid monitoring after statin initiation. J Clin Lipidol. 2020 Nov - Dec; 14(6):784-790.
Score: 0.084
-
Wilson L, Nair KV, Saseen JJ. Comparison of new-onset gout in adults prescribed chlorthalidone vs. hydrochlorothiazide for hypertension. J Clin Hypertens (Greenwich). 2014 Dec; 16(12):864-8.
Score: 0.056
-
Anderson SL, Trujillo JM, McDermott M, Saseen JJ. Determining predictors of response to exenatide in type 2 diabetes. J Am Pharm Assoc (2003). 2012 Jul-Aug; 52(4):466-71.
Score: 0.048
-
Maes ML, Saseen JJ, Wright G, Claus LW. Utilization of acute gout prophylaxis in the real world: a retrospective database cohort analysis. Clin Rheumatol. 2021 Mar; 40(3):1017-1026.
Score: 0.021
-
Graham JH, Sanchez RJ, Saseen JJ, Mallya UG, Panaccio MP, Evans MA. Clinical and economic consequences of statin intolerance in the United States: Results from an integrated health system. J Clin Lipidol. 2017 Jan - Feb; 11(1):70-79.e1.
Score: 0.016
-
Fixen CW, Saseen JJ, Vande Griend JP, Linnebur SA. Assessment of blood pressure in patients with hypertension aged 60-79 years before and after the publication of the 2014 Eighth Joint National Committee report. Ther Adv Cardiovasc Dis. 2016 Apr; 10(2):67-73.
Score: 0.015
-
Thompson LA, Saseen JJ, O'Bryant CL, Allen RR, Nair KV. Claims analysis of hypertension occurrence, severity changes and patterns of antihypertensive use in cancer patients receiving vascular endothelial growth factor inhibitors. J Oncol Pharm Pract. 2015 Aug; 21(4):258-67.
Score: 0.013
-
Libby AM, Fish DN, Hosokawa PW, Linnebur SA, Metz KR, Nair KV, Saseen JJ, Vande Griend JP, Vu SP, Hirsch JD. Patient-level medication regimen complexity across populations with chronic disease. Clin Ther. 2013 Apr; 35(4):385-398.e1.
Score: 0.013
-
Alford JC, Saseen JJ, Allen RR, Nair KV. Persistent use of against-label statin-fibrate combinations from 2003-2009 despite United States Food and Drug Administration dose restrictions. Pharmacotherapy. 2012 Jul; 32(7):623-30.
Score: 0.012
-
Nair KV, Tang B, Van Den Bos J, Zhang V, Saseen JJ, Naim A, Rahman M. Categorization of infliximab dose changes and healthcare utilization and expenditures for patients with rheumatoid arthritis in commercially insured and Medicare-eligible populations. Curr Med Res Opin. 2009 Feb; 25(2):303-14.
Score: 0.009
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|